Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of pulmonary arterial hypertension (PAH). The company applies Abelson Tyrosine Kinase inhibitor science to address serious cardiovascular and pulmonary diseases, advancing its lead candidate IkT-001Pro through late-stage clinical trials.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2025
Oct 2024
Create a free account to see which investors have funded this company.
Create Free Account
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
